Sutro biopharma

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting sutro biopharma pathways, sutro biopharma. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link.

Skip to main content. Sutro Biopharma, Inc. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. Vaxcyte, Inc.

Sutro biopharma

Key events shows relevant news articles on days with large price movements. Gossamer Bio Inc. GOSS 4. Kezar Life Sciences Inc. KZR 0. Ovid Therapeutics Inc. OVID 0. Vaxcyte Inc. PCVX 0. Trevi Therapeutics Inc. TRVI 2. XOMA Corp.

Vaxcyte, Inc.

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology. Learn More. Sutro Biopharma, Inc. Our Technology. Our innovative Research and development has resulted in six product candidates Our Pipeline Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. News Releases.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA. Sutro was named one of Fierce Biotech's Fierce 15 in

T1 motorsport

Endpoints News. Net profit margin. Net cash used or generated in investing activities such as purchasing assets. Cash and short-term investments Investments that are relatively liquid and have maturities between 3 months and one year. STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. The total amount of assets owned by a company. Effective tax rate. Previous close. Sutro Biopharma, Inc. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Skip to main content. Sutro Biopharma, Inc. Tools Tools. GOSS 4. Net cash used or generated for core business activities.

.

Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in Investments that are relatively liquid and have maturities between 3 months and one year. Dedicated to our Patients and Changing the Future of Oncology. OVID 0. Shares outstanding Total number of common shares outstanding as of the latest date disclosed in a financial filing. Net change in cash The amount by which a company's cash balance increases or decreases in an accounting period. PT in New York City. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Cash and short-term investments. The average number of shares traded each day over the past 30 days. Dividend yield. Net profit margin Measures how much net income or profit is generated as a percentage of revenue. Revenue The total amount of income generated by the sale of goods or services related to the company's primary operations.